

小動物用MRIを用いたてんかんモデル マウスにおけるけいれん発作発症に伴う 脳内変化の評価

**The Assessment of Brain Functions in the
Proconvulsants-provoked Convulsive Seizure Model
Mice using Magnetic Resonance Imaging**



○伊藤 康一、渡邊 正知
徳島文理大・香川薬・薬物治療



(様式2-A)口頭発表におけるCOI状態の開示
申告すべきCOI状態がない場合

日本てんかん学会 COI 開示

筆頭発表者名：伊藤 康一

演題発表に関連し、開示すべきCOI 関係にある 企業など
はありません。


薬剤治療抵抗性てんかん Pharmacoresistant Epileptics

てんかん有病率 → 100人に0.8~1人
(日本で約100万人、全世界では6000万人)

新しい作用機序に基づく
新規治療薬の開発が必要！



てんかん発作発症機構および
発作抑制機構の解明



(症候性てんかん40%, 特発性てんかん26%)
AED: 抗てんかん薬
Kwan et al., 2000, 343:314-319, N Engl J Med

てんかんの病因とBBB

The Etiology of Epilepsy and BBB

1. 血液脳関門 (Blood-brain barrier; BBB) との関係

- ✓ 薬物トランスポーター仮説

BBBに存在する薬物トランスポーター(排泄機構)の異常活性

- ✓ BBB機能不全仮説



2. 抗てんかん薬 (AED) 妥当性

- ✓ てんかん原性ネットワーク仮説

同一分類されたてんかん・発作型でも発症メカニズムが異なる

Basic Principle of Gd-Enhanced Magnetic Resonance Imaging (GdEMRI)


- ✓ Use **BBB impermeable Gadolinium (Gd)** as image MR contrast agent




BBB Breakdown Following Traumatic Brain Injury

No BBB disruption in control subject


Control enhancement



Permeability (K^{trans})




Extravascular volume (v_e)




Posttraumatic epilepsy patient enhancement


Increased BBB permeability in a 28-year-old PTE patient 10 days following TBI



(a)
 K^{trans}




v_e




Epileptic Seizures in PILO-SE mice




Experimental schedule



SE: Status Epileptics



Epileptic Seizures in PILO-SE mice



Stage	Seizures
0	normal
1	immobilization
2	facial, vibrissal and forelimb clonus (short myoclonic jerk)
3	myoclonic jerking consisted of a whole body jerk with or without irregular, bilateral forelimb movements
4	generalized clonic seizures (GCS) with kangaroo posture
5	generalized tonic-clonic seizures (GTCS) with loss of posture tone.



BBB Breakdown in PILO-SE mice

After PILO injection

T₁WI

TR: 500 msec
TE: 9 msec
NEX=8

T₂WI



TR: 2500 msec
TE: 69 msec
NEX=4

DWI


TR: 2500 msec
TE: 69 msec
b-factor: 800 sec/mm²
NEX=4

GdEMRI







TR: 500 msec
TE: 9 msec
NEX=4



Hippocampus,
amygdala and
piriform cortex




Changes in MR parameters following prolonged seizures

T₁WI			Atrophy: Cell loss
<hr/>			
	<u>Edema: Vasogenic</u>	<u>Cytotoxic</u>	
T₂WI			Gliosis
DWI			Gliosis?
<hr/>			
GdEMRI (T₁WI)			BBB leakage
<hr/>			




The underlying mechanisms of these changes are in most cases not well known.

Levetiracetam (E Keppra®)



- **Levetiracetam (LEV) is approved for treatment of partial, myoclonic, and tonic-clonic seizures.**
- **LEV, add-on therapy, is also effective for refractory epilepsy.**
(LEV improves memory in mild cognitive impairment?)
- **LEV binds to the synaptic vesicle protein SV2A, and inhibits presynaptic calcium channels to modulate of synaptic neurotransmitter release in the brain.**
- **The proposed therapeutic range for seizure control is 11 $\mu\text{g/mL}$ (60 μM) (5-30 $\mu\text{g/mL}$, 30-180 μM).**
- **Pharmacokinetics of LEV are affected by renal function.**

Effect of LEV on PILO-induced Seizures during Status Epilepticus



Video 2



Effects of LEV on BBB Breakdown in PILO-SE mice



Treatment with LEV after PILO injection

T₁WI
 TR: 500 msec
 TE: 9 msec
 NEX=8


T₂WI
 TR: 2500 msec
 TE: 69 msec
 NEX=4

DWI
 TR: 2500 msec
 TE: 69 msec
 b-factor: 800 sec/mm²
 NEX=4

GdEMRI
 TR: 500 msec
 TE: 9 msec
 NEX=4



Hippocampus,
 amygdala and
 piriform cortex




Effects of LEV on BBB Breakdown in PILO-SE mice

**% of SI increase
(vs pre PILO injection)**


$$C_t(\%) = \frac{R_t - R_{pre}}{R_{pre}} \times 100$$

C_t: % of change at the time point
R_t: SI in ROI at the time point
R_{pre}: SI in ROI prior to PILO injection
SI: Signal Intensity



Hypothetical Epileptogenic Events and Treatment

PILO-SE model



LEV服用でSEを抑制



BBB保護

まとめ Take home messages

◆PILO-SE後…

- 2日目で**Hippocampus**、**Amygdala**と**Piriform cortex**でT₂WとDWの信号強度が上昇 → 細胞障害性浮腫
- 17日目で**Amygdala**と**Piriform cortex**でT₁Wの信号強度が上昇 → 細胞死
- **BBB**透過性亢進
 - 内側側頭葉部位 (**Amygdala**) から起きる
 - ✓ 潜在期(latent)から慢性期(chronic)に増悪

◆1st PILO誘発GTCS後LEV投与…

- **PILO-SE**の発症を抑制
- **PILO**誘発**BBB**透過性亢進を抑制

◆LEV服用でけいれん準備性(seizure susceptibility)減弱または消失 → **BBB**保護作用？

Brain insults and BBB dysfunction

Prolonged seizures (SE, PFS)

Angiogenesis

Metabolic failure

Inflammation

BBB dysfunction

(Astrocyte dysfunction, Impaired homeostasis, Inflammation)

Neuronal (synaptic) hyperexcitability

Neuronal network reorganization

Epilepsy and Seizure